-
FDA advisory committees recommend approval of ultra rapid-acting mealtime insulin therapy
VALENCIA, Calif. — MannKind Corp. on Tuesday announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the Food and Drug Administration voted 13-to-1 to recommend that Afrezza (insulin human [rDNA origin]) inhalation powder be granted marketing approval by the FDA to improve glycemic control in adults with Type 1 diabetes and voted 14-to-0 to recommend that Afrezza be granted marketing approval by the FDA to improve glycemic control in adults with Type 2 diabetes.
-
Power E-Cigs debuts Express starter kit
MIAMI — Power E-Cigs, an electronic cigarette company, has launched Power E-Cigs Express Rechargeable Starter Kit. The kit is built with advanced Minimax technology, which provides extended battery life and a pleasing vapor experience for the consumer, the company said.